Mankind Pharma Complete Financial Statements
MANKIND • Review detailed financials to uncover trends, confirm thesis & journal trades
6 Years of Data
2025 - 2020
Complete Financial Data Export
Export complete financial statements for Mankind Pharma (MANKIND).
Downloads include all available records across all periods.
For market performance, see the
MANKIND stock price today
.
Profitability Ratios
Net Profit Margin
13.72%
2025 data
EBITDA Margin
26.80%
2025 data
Operating Margin
25.00%
2025 data
Return on Assets
1.87%
2025 data
Return on Equity
3.57%
2025 data
Balance Sheet Ratios
Current Ratio
0.93
2025 data
Debt to Equity
1.91
2025 data
Equity Ratio
52.48%
2025 data
Asset Turnover
0.14
2025 data
Year-over-Year Growth Analysis
Comparing Sept 2024 vs Sept 2025
Revenue Growth
+19.5%
Year-over-Year
Net Profit Growth
-21.1%
Year-over-Year
EBITDA Growth
+6.3%
Year-over-Year
Expense Growth
+25.2%
Year-over-Year
Assets Growth
+132.0%
Year-over-Year
Equity Growth
+52.1%
Year-over-Year
Liabilities Growth
+132.0%
Year-over-Year
Operating Cash Flow Growth
+12.1%
Year-over-Year
Investing Cash Flow Growth
-506.6%
Year-over-Year
Financing Cash Flow Growth
+204560.0%
Year-over-Year
Income Statement
Periods
₹ Crores
| Particulars | Sept 2025 | Mar 2025 | Jun 2025 | Sept 2024 | Mar 2024 | Jun 2024 | Dec 2024 | Sept 2023 | Mar 2023 | Jun 2023 | Dec 2023 | Sept 2022 | Mar 2022 | Jun 2022 | Dec 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3,791 | 3,333 | 3,653 | 3,173 | 2,517 | 2,976 | 3,286 | 2,772 | 2,103 | 2,642 | 2,682 | 2,457 | 1,764 | 2,200 | 2,130 |
| Expenses | 2,776 | 2,401 | 2,724 | 2,217 | 1,836 | 2,196 | 2,383 | 2,025 | 1,636 | 1,924 | 2,000 | 1,835 | 1,441 | 1,724 | 1,654 |
| EBITDA | 1,016 | 933 | 930 | 956 | 681 | 780 | 903 | 746 | 467 | 718 | 681 | 622 | 323 | 476 | 477 |
| Operating Profit Margin % | 25.00% | 22.00% | 24.00% | 28.00% | 24.00% | 23.00% | 26.00% | 25.00% | 20.00% | 25.00% | 23.00% | 24.00% | 17.00% | 21.00% | 21.00% |
| Depreciation | 222 | 231 | 219 | 101 | 100 | 103 | 187 | 97 | 85 | 87 | 110 | 79 | 47 | 78 | 85 |
| Interest | 170 | 191 | 171 | 7 | 9 | 11 | 221 | 9 | 5 | 6 | 9 | 10 | 13 | 16 | 13 |
| Profit Before Tax | 624 | 511 | 541 | 849 | 572 | 666 | 495 | 641 | 377 | 625 | 562 | 533 | 263 | 382 | 379 |
| Tax | 104 | 86 | 96 | 190 | 95 | 123 | 111 | 130 | 84 | 130 | 103 | 110 | 70 | 84 | 83 |
| Net Profit | 520 | 425 | 445 | 659 | 477 | 543 | 385 | 511 | 294 | 494 | 460 | 423 | 193 | 298 | 296 |
| Earnings Per Share (₹) | 12.39 | 10.19 | 10.62 | 16.31 | 11.76 | 13.39 | 9.46 | 12.51 | 7.13 | 12.15 | 11.33 | 10.48 | 4.74 | 7.30 | 7.09 |
Related Pages for Mankind Pharma
Additional stock information and data for MANKIND
Balance Sheet
Years
Annual Data
₹ Crores
| Particulars | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| ASSETS | |||||
| Total Assets | 27,760 | 11,963 | 9,715 | 9,148 | 6,373 |
| Current Assets | 6,988 | 6,568 | 4,328 | 4,407 | 3,907 |
| Fixed Assets | 19,005 | 4,545 | 4,251 | 3,588 | 1,664 |
| Capital Work in Progress | 826 | 282 | 550 | 702 | 372 |
| Investments | 2,042 | 2,568 | 1,346 | 1,110 | 1,512 |
| Other Assets | 5,887 | 4,568 | 3,568 | 3,749 | 2,824 |
| LIABILITIES | |||||
| Total Liabilities | 27,760 | 11,963 | 9,715 | 9,148 | 6,373 |
| Current Liabilities | 7,528 | 268 | 229 | 208 | 156 |
| Non-Current Liabilities | |||||
| SHAREHOLDERS' EQUITY | |||||
| Total Equity | 14,568 | 9,576 | 7,623 | 6,316 | 4,863 |
| Share Capital | 41 | 40 | 40 | 40 | 40 |
| Reserves & Surplus | 14,291 | 9,323 | 7,395 | 6,115 | 4,682 |
Cash Flow Statement
Periods
₹ Crores
| Particulars | March 2025 | March 2024 | March 2023 | March 2022 | March 2021 | March 2020 |
|---|---|---|---|---|---|---|
| Operating Activities | 2,413 | 2,152 | 1,813 | 920 | 1,137 | 1,070 |
| Investing Activities | -12,624 | -2,081 | -1,052 | -1,369 | -1,222 | -436 |
| Financing Activities | 10,233 | 5 | -740 | 605 | -8 | -531 |
| Net Cash Flow | 22 | 77 | 22 | 156 | -92 | 103 |